Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation

Journal of Neurochemistry

Volumn 88, Issue 2, 2004, Pages 494-501

  Dehmer, Thomas ^a   Heneka, Michael T ^b   Sastre, Magdalena ^b   Dichgans, Johannes ^a   Schulz, Jörg B ^a,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Inducible nitric oxide synthase; Nitrotyrosine; Nuclear factor kappaB; Parkinson's disease; Peroxisome pioglitazone; Proliferator activated receptor gamma

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROTYROSINE; GLIAL FIBRILLARY ACIDIC PROTEIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TYROSINE 3 MONOOXYGENASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CATECHOLAMINERGIC SYSTEM; CELL ACTIVATION; CELL DEATH; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DOPAMINERGIC SYSTEM; ENZYME ACTIVATION; GLIA CELL; INHIBITION KINETICS; MICROGLIA; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; WESTERN BLOTTING;

ANIMALIA;

EID: 0347087323     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.02210.x     Document Type: Article

References (44)

1. Beg A. A., Sha W. C., Bronson R. T., Ghosh S. and Baltimore D. (1995) Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376, 167-170.
2. Berger J. and Moller D. E. (2002) The mechanisms of action of PPARs. Annu. Rev. Med. 53, 409-435.
3. Berger J., Bailey P., Biswas C., Culliman C. A., Doebber T. W., Hayes N. S., Saperstein R., Smith R. G. and Leibowitz M. D. (1996) Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 137, 4189-4195.
4. Braissant O., Foufelle F., Scotto C., Dauca M. and Wahli W. (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137, 354-366.
5. Breidert T., Callebert J., Heneka M. T., Landreth G. E., Launay J. M. and Hirsch E. C. (2002) Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82, 615-624.
6. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P. and Evans R. M. (2001) PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7, 48-52.
7. Chinetti G., Griglio S., Antonucci M., Torra I. P., Delerive P., Majd Z., Fruchart J. C., Chapman J., Najib J. and Staels B. (1998) Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273, 25573-25580.
8. Colville-Nash P. R., Qureshi S. S., Willis D. and Willoughby D. A. (1998) Inhibition of inducible nitric oxide synthasc by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. J. Immunol. 161, 978-984.
9. Dehmer T., Lindenau J., Haid S., Dichgans J. and Schulz J. B. (2000) Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 74, 2213-2216.
10. Delerive P., Gervois P., Fruchart J. C. and Staels B. (2000) Induction of IkappaBalpha expression as a mechanism contributing to the antiinflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J. Biol. Chem. 275, 36703-36707.
11. Diab A., Deng C., Smith J. D., Hussain R. Z., Phanavanh B., Lovett-Racke A. E., Drew P. D. and Racke M. K. (2002) Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168, 2508-2515.
12. Du Y., Ma Z., Lin S. et al. (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl Acad. Sci. USA 98, 14669-14674.
13. Eberhardt O., Coelln R. V., Kugler S. et al. (2000) Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 20, 9126-9134.
14. de Erausquin G. A., Hyrc K., Dorsey D. A. et al. (2003) Nuclear translocation of nuclear transcription factor-kappa B by alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors leads to transcription of p53 and cell death in dopaminergic neurons. Mol. Pharmacol. 63, 784-790.
15. Feinstein D. L., Galea E., Gavrilyuk V., Brosnan C. F., Whitacre C. C., Dumitrescu-Ozimek L., Landreth G. E., Pershadsingh H. A., Weinberg G. and Heneka M. T. (2002) Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51, 694-702.
16. Ferrante R. J., Hantraye P., Brouillet E. and Beal M. F. (1999) Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Res. 823, 177-182.
17. Franklin K. B. J. and Paxinos G. (1996) The Mouse Brain in Stereotaxic Coordinates. Academic Press, Sydney.
18. Gao H. M., Jiang J., Wilson B., Zhang W., Hong J. S. and Liu B. (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 81, 1285-1297.
19. Ghosh S. and Karim M. (2002) Missing pieces in the NF-kappaB puzzle. Cell 109, S81-S96.
20. Hantraye P., Brouillet E., Ferrante R., Palfi S., Dolan R., Matthews R. T. and Beal M. F. (1996) Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat. Med. 2, 1017-1021.
21. Heneka M. T., Feinstein D. L., Galea E., Gleichmann M., Wullner U. and Klockgether T. (1999) Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J. Neuroimmunol. 100, 156-168.
22. Heneka M. T., Klockgether T. and Feinstein D. L. (2000) Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase and cell death in vivo. J. Neurosci. 20, 6862-6867.
23. Hunot S., Brugg B., Ricard D., Michel P. P., Muriel M. P., Ruberg M., Faucheux B. A., Agid Y. and Hirsch E. C. (1997) Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc. Natl Acad. Sci. USA 94, 7531-7536.
24. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debre P., Agid Y., Dugas B. and Hirsch E. C. (1999) FcepsilonRIl/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 19, 3440-3447.
25. Jiang C., Ting A. T. and Seed B. (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86.
26. Kim E. J., Kwon K. J., Park J. Y., Lee S. H., Moon C. H. and Baik E. J. (2002) Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res. 941, 1-10.
27. Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M. and Kliewer S. A. (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272, 3406-3410.
28. Lemberger T., Desvergne B. and Wahli W. (1996) Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu. Rev. Cell Dev. Biol. 12, 335-363.
29. Li M., Pascual G. and Glass C. K. (2000) Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. Mol. Cell. Biol. 20, 4699-4707.
30. Liberatore G. T., Jackson-Lewis V., Vukosavic S., Mandir A. S., Vila M., McAuliffe W. G., Dawson V. L., Dawson T. M. and Przedborski S. (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5, 1403-1409.
31. Lipton S. A. (1997) Janus faces of NF-kappa B: neurodestruction versus neuroprotection. Nat Med. 3, 20-22.
32. Maeshiba Y., Kiyota Y., Yamashita K., Yoshimura Y., Motohashi M. and Tanayama S. (1997) Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 47, 29-35.
33. Nomura Y. (2001) NF-kappaB activation and IkappaB alpha dynamism involved in iNOS and chemokine induction in astroglial cells. Life Sci. 68, 1695-1701.
34. Pennathur S., Jackson-Lewis V., Przedborski S. and Heinecke J. W. (1999) Mass spectrometric quantification of 3-nitrotyrosine, orthotyrosine, and o,o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J. Biol. Chem. 274, 34621-34628.
35. Petrova T. V., Akama K. T. and Van Eldik L. J. (1999) Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2. Proc. Natl Acad. Sci. USA 96, 4668-4673.
36. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V. L. and Dawson T. M. (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl Acad. Sci. USA 93, 4565-4571.
37. Ricote M., Li A. C., Willson T. M., Kelly C. J. and Glass C. K. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82.
38. Schulz J. B., Matthews R. T., Mugit M. M., Browne S. E. and Beal M. F. (1995) Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64, 936-939.
39. Straus D. S., Pascual G., Li M., Welch J. S., Ricote M., Hsiang C. H., Sengchanthalangsy L. L., Ghosh G. and Glass C. K. (2000) 15-Deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc. Natl Acad. Sci. USA 97, 4844-4849.
40. Teismann P., Schwaninger M., Weih F. and Ferger B. (2001) Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease. Neuroreport 12, 1049-1053.
41. Tontonoz P., Graves R. A., Budavari A. I., Erdjument-Bromage H., Lui M., Hu E., Tempst P. and Spiegelman B. M. (1994) Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPARgamma and RXR alpha. Nucleic Acids Res. 22, 5628-5634.
42. Vamecq J. and Latruffe N. (1999) Medical significance of peroxisome proliferator-activated receptors. Lancet 354, 141-148.
43. West M. J. (1999) Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci. 22, 51-61.
44. Wu D. C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D. K., Ischiropoulos H. and Przedborski S. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 1763-1771.